A

Apogee Clinical Research LLC | Huntsville, AL

Research site

(Unclaimed)

Location

185 Chateau Drive SouthWest Suite 301, Huntsville, Alabama, United States of America

Site insights

Top conditions

Top treatments

Empagliflozin

Bardoxolone Methyl

MZE829

BI 690517

Povetacicept

PF-07321332

KBP-5074

Vicadrostat

Parent organization

This site is a part of Apogee Clinical Research LLC

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 7 total trials

A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease

Enrolling

Proteinuric Kidney Disease

Drug: MZE829

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

This study is open to adults with chronic kidney disease (CKD) that is at risk of getting worse. People who have taken a specific type of medication...

Enrolling

Chronic Kidney Disease

Drug: Vicadrostat

Drug: Empagliflozin

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study....

Enrolling

Kidney Disease, Chronic

Drug: Placebo matching BI 690517

Drug: Empagliflozin

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserv...

Enrolling

Immunoglobulin A Nephropathy

Drug: Placebo (matched to Povetacicept)

Drug: Povetacicept